Braunwald Cell-Based Therapy in Cardiac Regeneration 133 therapy rarely uses a single
administration of a drug and it would seem logical to deliver cells repeatedly in treating a …

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by
remodeling of the pulmonary arteries, increased pulmonary infiltrates, loss of vascular cross …

Right-sided heart failure (RHF) occurs from impaired contractility of the right ventricle (RV)
caused by pressure, volume overload, or intrinsic myocardial contractile dysfunction leading …

Cell therapies are an emerging focus for neonatal research, with benefits documented for
neonatal respiratory, neurological, and cardiac conditions in pre-clinical studies. Umbilical …

Background: Congenital heart disease (CHD) constitutes the most prevalent and
heterogeneous group of congenital anomalies. Although surgery remains the gold standard …

Hypoplastic left heart syndrome is a type of congenital heart disease characterized by
underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if …

Stem cell transplantation is a potentially important means of treatment for a number of
disorders. Two different stem cell populations of interest are mononuclear umbilical cord …

Long-term engraftment and phenotype correction has been difficult to achieve in humans
after in utero stem cell transplantation mainly because of allogeneic rejection. Autologous …

Pulmonary arterial hypertension (PAH) remains a deadly disease, and there currently is no
cure for this life-threating medical problem. The average lifespan is about 5 to 7 years after …

Right ventricular failure (RVF) is a common cause of death in patients suffering from
pulmonary arterial hypertension (PAH). The current treatment for PAH only moderately …